- Home
- KALA vs DYAI Comparison
KALA vs DYAI Comparison
Compare KALA & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- DYAI
- Stock Information
- Founded
- KALA 2009
- DYAI 1979
- Country
- KALA United States
- DYAI United States
- Employees
- KALA N/A
- DYAI N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KALA Health Care
- DYAI Health Care
- Exchange
- KALA Nasdaq
- DYAI Nasdaq
- Market Cap
- KALA 26.2M
- DYAI 28.3M
- IPO Year
- KALA 2017
- DYAI 2004
- Fundamental
- Price
- KALA $5.48
- DYAI $0.98
- Analyst Decision
- KALA Strong Buy
- DYAI Strong Buy
- Analyst Count
- KALA 3
- DYAI 1
- Target Price
- KALA $14.00
- DYAI $6.00
- AVG Volume (30 Days)
- KALA 125.5K
- DYAI 64.2K
- Earning Date
- KALA 08-05-2025
- DYAI 08-12-2025
- Dividend Yield
- KALA N/A
- DYAI N/A
- EPS Growth
- KALA N/A
- DYAI N/A
- EPS
- KALA N/A
- DYAI N/A
- Revenue
- KALA N/A
- DYAI $3,554,344.00
- Revenue This Year
- KALA N/A
- DYAI $22.56
- Revenue Next Year
- KALA N/A
- DYAI $30.95
- P/E Ratio
- KALA N/A
- DYAI N/A
- Revenue Growth
- KALA N/A
- DYAI 57.59
- 52 Week Low
- KALA $2.92
- DYAI $0.91
- 52 Week High
- KALA $11.20
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- KALA 55.78
- DYAI 49.96
- Support Level
- KALA $4.36
- DYAI $0.91
- Resistance Level
- KALA $7.00
- DYAI $1.02
- Average True Range (ATR)
- KALA 0.75
- DYAI 0.05
- MACD
- KALA 0.07
- DYAI 0.01
- Stochastic Oscillator
- KALA 49.17
- DYAI 46.80
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.